3SBio Inc. TRSBF

Company Overview

3SBio Inc. is a China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic medicines and specialty pharmaceuticals. The company operates primarily in the biotechnology and pharmaceutical industries, with a concentration on oncology, nephrology, autoimmune diseases, dermatology, and metabolic disorders. Listed on the Hong Kong Stock Exchange under the ticker 1530.HK and traded in the U.S. over-the-counter market as TRSBF, 3SBio has established itself as one of the larger domestic biotechnology companies in China with integrated development and manufacturing capabilities.

The company’s primary revenue drivers include marketed biologic therapies such as recombinant human thrombopoietin products, erythropoietin products, and oncology-related therapeutics. Key products include TPIAO, Yisaipu, Cipterbin, and Mandi. 3SBio serves hospitals, physicians, and healthcare systems across China while also expanding selected products internationally through licensing and commercialization partnerships. The company traces its origins to the early 1990s and evolved from a domestic biologics producer into a diversified biotechnology enterprise through internal R&D expansion, acquisitions, and strategic licensing arrangements.